SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Jemal A, Siegal R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin. 2006; 56: 106130.
  • 2
    Saeter G. Chemotherapy for adult soft tissue sarcoma: does it work? Acta Orthop Scand. 1997; 273( Suppl): 139144.
  • 3
    Antman KH, Elias AD. Chemotherapy for advanced soft tissue sarcomas. Semin Surg Oncol. 1998; 4: 5358.
  • 4
    Gottlieb JA, Benjamin RS, Baker LH, et al. Role of DTIC (NSC-45388) in the chemotherapy of sarcomas. Cancer Treat Rep. 1976; 60: 199205.
  • 5
    Patel SR, Gandhi V, Jenkins J, et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J Clin Oncol. 2001; 19: 34833489.
  • 6
    Hensley ML, Maki R, Venkatraman E, et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002; 20: 28242831.
  • 7
    Leu KM, Ostruszka LJ, Shewach D, et al. Laboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcoma. J Clin Oncol. 2004; 22: 17061712.
  • 8
    Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993; 11: 12761285.
  • 9
    Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol. 1993; 11: 12691275.
  • 10
    Miyazaki K, Kobayashi M, Natsume T, et al. Synthesis and antitumor activity of novel dolastatin analogs. Chem Pharm Bull. 1995; 43: 17061718.
  • 11
    Pettit GR, Kamano Y, Herald CL, et al. The isolation and structure of a remarkable marine animal antineoplastic constituent: dolastatin 10. J Am Chem Soc. 1987; 109: 68836885.
  • 12
    Pettit GR, Singh SB, Hogan F, et al. The absolute configuration and synthesis of natural (−) dolastatin 10. J Am Chem Soc. 1987; 111: 54635465.
  • 13
    Pettit GR, Kamano Y, Herald CL, et al. Isolation of dolastatin10-15 from the marine mollusk Dolabella auricularia. Tetrahedron. 1993; 49: 91519170.
  • 14
    Hamada Y, Hayashi K, Shiori T. Efficient stereoselective synthesis of dolastatin 10, an antineoplastic peptide from a sea hare. Tetrahedron Lett. 1991; 32: 931934.
  • 15
    Natsume T, Watanabe J, Tamaoki S, Fujio N, Miyasaka K, Kobayashi M. Characterization of the interaction of TZT-1027, a potent anti-tumor agent, with tubulin. Jpn J Cancer Res. 2000; 91: 737747.
  • 16
    Watanabe J, Natsume T, Fujio N, Miyasaka K, Kobayashi M. Induction of apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis. 2000; 5: 345353.
  • 17
    Kobayashi M, Natsume T, Tamaoki S, et al. Antitumor activity of TZT-1027, a novel dolestatin-10 derivative. Jpn J Cancer Res. 1997; 88: 316327.
  • 18
    Otani M, Natsume T, Watanabe JI, et al. TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death. Jpn J Cancer Res. 2000; 91: 837844.
  • 19
    Fujita F, Koike M, Fujita M, Sakamoto Y, Tsukagoshi S. Antitumor effects of TZT-1027, a novel dolastatin 10 derivative, on human tumor xenografts in nude mice. Jpn J Cancer Chemother. 2000; 27: 451458.
  • 20
    Nitani H, Hasegawa K, et al. Phase I studies of TZT-1027, a novel inhibitor of tubulin polymerization. Proc NCI-EORTC Symposium on New Drug Cancer Therapy. 1998; 10.
  • 21
    Yamamoto N, Andoh M, Kawahara M, et al. Phase I study of TZT-1027, an inhibitor of tubulin polymerization, given weekly X 3 as a 1-hour intravenous infusion in patients with solid tumors. Proc Am Soc Clin Oncol. 2002; 21: 106a.
  • 22
    Horti J, Juhasz E, Bodrogi I, et al. A phase I trial of TZT-1027, an inhibitor of tubulin polymerization, in patients with advanced non-small cell lung cancer (NSCLC). Proc AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. 2003.
  • 23
    Schoffski P, Thate B, Beutel G, et al. Phase I and pharmacokinectic study of TZT-1027, a novel synthetic dolastatin derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer. Ann Oncol. 2004; 15: 671679.
  • 24
    de Jonge MJ, van der Gaast A, Planting AS, et al. Phase I and pharmacokinectic study of the dolastatin analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid tumors. Clin Cancer Res. 2005; 11: 38063813.
  • 25
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment of solid tumours. J Natl Cancer Inst. 2000; 92: 205216.
  • 26
    Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649655.
  • 27
    National Cancer Institute. Common terminology criteria for adverse events (CTCAE). Version 3.0. Bethesda, MD: National Cancer Institute; 2003.
  • 28
    Sargent DJ, Chan V, Goldberg RM. A three outcome design for phase II clinical trials. Control Clin Trials. 2001; 22: 117125.
  • 29
    Schwartsmann G, Brondani da Rocha A, Berlinck RG, et al. Marine organisms as a source of new anticancer agents. Lancet Oncol. 2001; 2: 221225.